Stock traders buy high volume of call options on Vanda Pharmaceuticals (NASDAQ: VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was the recipient of unusually large options trading on Friday. Stock traders bought 4,024 call options on the company. This is an increase of 1,070% over the average volume of 344 call options.

Vanda Pharmaceuticals stock traded down $ 0.46 on Friday, reaching $ 15.38. The company’s shares had a trading volume of 260,873 shares, compared to its average volume of 347,703. The company has a market capitalization of $ 856.85 million, a price-to-earnings ratio of 25.21 and a beta of 0.44. The company’s fifty-day average mobile price is $ 17.07, and its 200-day average mobile price is $ 17.57. Vanda Pharmaceuticals has a twelve month low of $ 13.36 and a twelve month high of $ 21.86.

Vanda Pharmaceuticals (NASDAQ: VNDA) last released its quarterly earnings data on Wednesday, November 3. The biopharmaceutical company reported EPS of $ 0.14 for the quarter, missing analyst consensus estimates of $ 0.20 per ($ 0.06). The company posted revenue of $ 70.10 million in the quarter, compared to analysts’ estimates of $ 73.50 million. Vanda Pharmaceuticals recorded a return on equity of 7.23% and a net margin of 12.77%. During the same period of the previous year, the company posted EPS of $ 0.11. As a group, equity research analysts predict that Vanda Pharmaceuticals will post earnings per share of 0.55 for the current year.

In addition, CEO Mihael Hristos Polymeropoulos sold 46,200 shares of Vanda Pharmaceuticals in a transaction dated Wednesday, December 1. The stock was sold for an average price of $ 16.00, for a total trade of $ 739,200.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 6.10% of the capital is held by insiders.

(A d)

This guide will help you identify and execute an options trading strategy that matches your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

A number of hedge funds and other institutional investors have recently increased or reduced their stakes in the stock. Meeder Asset Management Inc. increased its holdings of Vanda Pharmaceuticals shares by 3,824.8% in the third quarter. Meeder Asset Management Inc. now owns 4,435 shares of the biopharmaceutical company valued at $ 77,000 after acquiring an additional 4,322 shares in the last quarter. FORA Capital LLC purchased a new stake in Vanda Pharmaceuticals shares in the second quarter valued at approximately $ 129,000. Schonfeld Strategic Advisors LLC purchased a new equity stake in Vanda Pharmaceuticals in the third quarter valued at approximately $ 172,000. Grantham Mayo Van Otterloo & Co. LLC purchased a new stake in Vanda Pharmaceuticals shares in the third quarter valued at approximately $ 225,000. Finally, Profund Advisors LLC purchased a new stake in Vanda Pharmaceuticals shares in the second quarter valued at approximately $ 231,000. Institutional investors and hedge funds hold 98.42% of the company’s shares.

Meanwhile, Zacks Investment Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report released on Friday. One equity research analyst rated the stock with a sell rating, two issued a hold rating, and one issued a buy rating for the company’s stock. Based on data from, the company currently has a consensus rating of “Hold” and an average price target of $ 18.50.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals, Inc is engaged in the development and commercialization of therapies for significant unmet medical needs. The company intends to treat schizophrenia, jet lag disorders, atopic dermatitis, central nervous system disorders and circadian sleep rhythm disorders. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin and AQW051.

Featured article: What do investors mean by earnings per share?

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Vanda Pharmaceuticals now?

Before you consider Vanda Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the wider market takes hold … and Vanda Pharmaceuticals was not on the list.

While Vanda Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

Comments are closed.